Please provide your email address to receive an email when new articles are posted on . A training course supports early-stage researchers in laboratory and translational science. The goal is to ...

Ahead of his talk at the 7th Annual Allogeneic Cell Therapies Summit, Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and large-scale ...

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

“Stem cell therapy and research are still effectively banned in South Africa,” Dr Mia said. “That hasn’t changed in law. What ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

When CAR T-therapies first reached the market, they came with warnings and monitoring requirements to protect patients — for good reason. Engineering a patient’s own immune cells into targeted cancer ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

For years, chimeric antigen receptor (CAR) T cell therapies have led the way in cell-based immunotherapy, offering hope to many patients with certain blood cancers. But now, researchers believe the ...

This story is the first in an occasional series following Louisiana’s first patients to receive gene therapy for sickle cell disease. On the third floor of Manning Family Children’s Hospital in New ...